Duration of Acyclovir Treatment for Herpes Virus CNS Infection
For confirmed herpes simplex encephalitis, continue intravenous acyclovir for 14-21 days, and perform a repeat lumbar puncture at the end of treatment to confirm CSF is negative for HSV by PCR; if still positive, continue IV acyclovir with weekly PCR testing until negative. 1
Treatment Duration Algorithm
Standard Duration: 14-21 Days
The original trials used 10-day courses, but clinical relapses were subsequently documented, leading to the current recommendation of 14-21 days of IV acyclovir at 10 mg/kg every 8 hours for adults with normal renal function 2, 1. This extended duration addresses the risk of viral persistence and relapse that occurred with shorter treatment courses 3.
End-of-Treatment Assessment
At 14-21 days, perform repeat lumbar puncture:
- If CSF PCR is negative for HSV: Stop acyclovir 1
- If CSF PCR remains positive: Continue IV acyclovir with weekly PCR monitoring until CSF clears 1
A negative CSF PCR at the end of therapy correlates with better outcomes, making this repeat testing clinically valuable 2.
Special Populations
Neonates
Higher doses and longer duration are required: 20 mg/kg IV every 8 hours for 21 days reduces mortality to 5% in neonatal HSV encephalitis, compared to higher mortality with standard dosing 2, 4, 5, 6. The 21-day duration at higher doses has eliminated documented relapses in neonates, whereas 8% relapsed with 10-day courses at lower doses 2.
Immunocompromised Patients
Consider extended therapy beyond 21 days if CSF remains PCR-positive, as these patients may have prolonged viral replication 1.
Early Discontinuation Criteria
You may stop acyclovir earlier than 14 days only if:
- An alternative diagnosis is confirmed, OR
- HSV PCR is negative on two occasions 24-48 hours apart AND MRI is not characteristic for HSV encephalitis, OR
- HSV PCR is negative once >72 hours after symptom onset AND patient has unaltered consciousness AND normal MRI (performed >72 hours after onset) AND CSF white cells <5 × 10⁶/L 1
Critical caveat: Do not stop acyclovir based on a single negative CSF PCR if clinical suspicion remains high, as early sampling (<72 hours) can yield false negatives 1.
Prognostic Factors Affecting Outcomes
Mortality and morbidity remain significant despite treatment. Poor outcome predictors include:
- Age >30 years
- Glasgow Coma Score <6
- Duration of symptoms >4 days before starting acyclovir (mortality 28% vs 8% if started <4 days) 2
- Delay >2 days between hospital admission and acyclovir initiation 2
These factors underscore the importance of early empiric treatment when HSV encephalitis is suspected, even before confirmatory testing returns.
Safety Monitoring
Monitor for nephrotoxicity: Acyclovir crystalluria can cause reversible obstructive nephropathy in up to 20% of patients, typically manifesting after 4 days of IV therapy 1. Ensure adequate hydration and infuse over at least 1 hour 7. Dose adjustment is required for renal impairment 7.
Monitor neutrophil counts in neonates: If absolute neutrophil count falls below 500/mm³, consider dose reduction or granulocyte colony-stimulating factor 4, 6.
Role of Oral Valacyclovir
While oral acyclovir does not achieve adequate CSF levels, valacyclovir (the valine ester with superior bioavailability) may have a role in ongoing treatment for patients with persistent HSV detection in CSF after 2-3 weeks of IV therapy 1. However, this remains investigational, and IV acyclovir remains the standard route throughout the treatment course.